Patent applications published 23 June 2010

Published: 15-Jul-2010
Patient Experience

Selected patent applications from the weekly European Patents Bulletin


  • Compsns and means for treating uterine leiomyomata, leiomyoma, myoma, endometriosis, adenomyosis and related disorders by mifepristone
    Bio-Pro Medical 2197415*

  • Pharmaceutical formulation of valsartan
    Novartis 2197416*

  • Pharmaceutical compsn comprising S-nitrosoglutathione and polysaccharide
    Biotech Hungary Kutató És Fejlesztési Kft 2197417*

  • Biodegradable implants with controlled bulk density
    Durect 2197418*

  • Medical devices and methods including polymers having biologically active agents therein
    Medtronic 2197419*

  • Controlled release azithromycin solid dosage forms
    Dow Pharmaceutical Sciences 2197420*

  • Solid state protein formulation
    Amgen 2197421*

  • Haemostatic agent compsn and method of delivery
    Mentkow, Jack; Mentkow, Lisa 2197422*

  • Improved pharmaceutical compsn containing a selective oestrogen receptor modulator and method for the preparation thereof
    Pharmathen 2197423*

  • Improved pharmaceutical compsn containing antiviral agent and method for the preparation thereof
    Pharmathen 2197424*

  • Solid dispersion product of N-aryl urea-based drugs
    Abbott GmbH 2197425*

  • Solid dispersion product containing N-aryl urea-based compound
    Abbott GmbH 2197426*

  • A multilayer pharmaceutical compsn comprising an antagonist in a first layer and an agonist in a second layer
    Alpharma 2197427*

  • Improved pharmaceutical compsn containing a pyrrolidone anticonvulsant agent and method for the preparation thereof
    Pharmathe 2197428*

  • Particulate compsns for delivery of poorly soluble drugs
    Nanotherapeutics 2197429*

  • Stable chewing gum compsns comprising maltitol and providing rapid release of nicotine
    NicoNovum 2197430*

  • Modulation of growth hormone, DHEA, and cortisol with positive modulators of AMPA type glutamate receptors
    Olas Pharmaceuticals 2197431*

  • Use of diazoxide for suppressing the plasma insulin level in a mammal
    Co-öperatieve Mirzog 2197432*

  • Regulated GLP-1 and SGLT-1 in gastrointestinal cells
    Mount Sinai School of Medicine 2197433*

  • Resveratrol-containing compsns for modulating gene product concentration or activity
    Resveratrol Partners 2197434*

  • Novel nutraceutical compsns containing thymol and/or P-cymene of plant extracts for cognition
    DSM IP Assets 2197435*

  • Preparation and a component intended to be added to a tobacco product
    Biohit 2197436*

  • Use of oleocanthal for the treatment of lipid metabolism disorders
    B.C. Development; Sprim 2197437*

  • Heterocyclic compounds as CRTH2 receptor antagonists
    Chemietek 2197438*

  • Pharmaceutical compsn for treating hepatitis C virus infection comprising HMG_CoA reductase inhibitor and bile acid
    Hanall Pharmaceutical 2197439*

  • Combinations of imazalil and hydroxypyridones
    Janssen Pharmaceutica 2197440*

  • Compounds which have their activity at M1 receptor and their uses in medicine
    Glaxo Group 2197441*

  • Polo-like kinase inhibitors
    Takeda Pharmaceutical Co 2197442*

  • Compsns and methods for effecting NAD+ levels using a nicotinamide phosporibosyl transferase inhibitor
    Gemin X Pharmaceuticals Canada 2197443*

  • Novel combination of therapeutic agents
    Glaxo Group 2197444*

  • TSH receptor antagonising tetrahydroquinoline compounds
    NV Organon 2197445*

  • Preparation of ziprasidone hydrochloride monohydrate
    Dr Reddy’s Laboratories 2197446*

  • Antifungal agents
    Merck Sharp & Dohme 2197447*

  • Dosing regimen
    Elan Pharma International 2197448*

  • Novel ophthalmic compsns
    Sun Pharma Advanced Research 2197449*

  • 7-keto DHEA for psychiatric use
    Sagerman, Sharon; Brown, Richard 2197450*

  • 2-amino-2,7-dideoxy-alpha-D-glycero-D-gluco-heptopyranosyl inhibitors of positive sense single-stranded RNA envelope viruses
    Institute for Hepatitis and Virus Research 2197451*

  • DHEAs inhalation compsn
    Epigenesis Pharmaceutical 2197452*

  • Azithromycin for treatment of skin disorders
    Dow {Pharmaceutical Sciences 2197453*

  • Pharmaceutical compsns for administering oligonucleotides
    IDEXX Laboratories 2197454*

  • Compsns and methods for the identification of inhibitors of retroviral infection
    North Carolina State University 2197455*

  • Ophthalmic compsns based on tamarind seed polysaccharide and hyaluronic acid
    RMFA Trading 2197456*

  • Therapeutic and vaccine polyelectrolyte nanoparticle compsns
    Apama Biosciences 2197457*

  • Cell compsns for tissue regeneration
    Regenentech 2197458*

  • A lung-surfactant product
    Larsson, Marcus; Herbst, Andreas 2197459*

  • Compsns comprising Siraitia grosvenori extracts and methods for the treatment of infection
    Prendergast, Patrick T 2197460*

  • Ophthalmic compsns comprising calcineurin inhibitors or MTOR inhibitors
    Lux Biosciences 2197461*

  • Use of IL-1 receptor peptide, alone or in combination with D-ala-GLN-octadecyl ester, as a therapeutic agent
    Mondobiotech Laboratories 2197462*

  • Use of RGDSPASSKP and optionally angiotensin II as therapeutic agents in the treatment of e.g. S. pneumoniae infections
    Mondobiotech Laboratories 2197463*

  • Use of the peptide SFLLR-OH and meuramyl depetide as therapeutic agents
    Mondobiotech Laboratories 2197464*

  • Use of angiotensin II as a therapeutic agent in the treatment of eg S. pneumoniae infection
    Mondobiotech Laboratories 2197465*

  • Use of retrocyclin-1 as a therapeutic agent for the treatment of HCMV infections
    Mondobiotech Laboratories 2197466*

  • Use of adrenomedullin as a therapeutic agent of the treatment of excessive angiogenesis
    Mondobiotech Laboratories 2197467*

  • Pegylation by the dock and lock (DNL) technique
    IBC Pharmaceuticals 2197468*

  • Use of NF-KABBAB inhibitor SN50 and optionally angiotensin III as therapeutic agents in the treatment of eg HBV infection
    Mondobiotech Laboratories 2197469*

  • Use of BUBUC and optionally EAMART1 (26-35) as a therapeutic agent for the treatment of HCMV infections
    Mondobiotech Laboratories 2197470*

  • Use of the peptides MAIPPKKNQDK (cow kappa casein 106-116) and/or YGFQNA (serorphin) as therapeutic agents
    Mondobiotech Laboratories 2197471*

  • Use of band 3 protein and PACAP-27 as a therapeutic agent
    Mondobiotech Laboratories 2197472*

  • Therapeutic uses of B-type natriuretic peptide and human growth hormone 1-43
    Mondobiotech Laboratories 2197473*

  • Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method of screening compounds that prevent apoptosis
    Charité - Universitätsmedizin Berlin 2197474*

  • Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission
    Uutech 2197475*

  • Use of VEGFR-2 inhibitors for treating metastatic cancer
    Bristol-Myers Squibb 2197476*

  • Use of LVV-hemorphin-6 and optionally AF12198 as therapeutic agent(s)
    Mondobiotech Laboratories 2197477*

  • Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
    Uutech 2197478*

  • Inositol pyrophosphates determine exocytic capacity
    BioCrine 2197479*

  • Compsn for treating lung cancers, particularly of non-small lung cancers
    CureVac 2197481*

See more

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

Read more
The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape

Trending Articles

  1. Pfizer wins battle over Viagra trademark Energy drinks brand Viaguara cannot be registered as an EU trademark
  2. Patent applications published 7 July 2010 Selected patent applications from the weekly European Patents Bulletin
  3. Genmab says GSK has settled patent case with Genentech Concerning two US patents for ofatumumbab
  4. Boehringer Ingelheim suffers Spiriva patent blow in India Indian patent office has revoked a patent granted for tiotropium bromide monohydrate under the Spiriva brand, paving the way for Cipla to continue selling its generic version in the Indian market
  5. Phillips-Medisize acquires mini-tablet dispenser patent The US company has acquired exclusive ownership of the patent from a global pharmaceutical company and expects to make the product available by early 2020

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Digital

Pharma cybersecurity challenges: a holistic prescription

The pharmaceutical sector remains a prime target for cyberattacks. As an industry built on innovation, with extensive investments in research and development (R&D), intellectual property (IP) and patient information, it bridges the divide between business and healthcare, becoming a hotspot in the health data threat landscape
Regulatory

Pharmaseal reaches milestone in crowdfunding campaign

The company was first founded in 2016
Patient Experience

Ilya Pharma awarded engineered lactic acid bacterial strain patent

The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Pharmaceutical

A card in the competition for COVID-19 drug supply

The patent system has come under pressure both politically and, more recently, as pharma companies scale-up their operations to make large amounts of drugs available to treat COVID-19, reports Paul England, Senior Professional Support Lawyer at Taylor Wessing
Ingredients

Sigrid Therapeutics obtains US patent for silica-based biomaterial SiPore15 for the treatment and prevention of obesity

Mesoporous silica particles (MSP) are a type of ingestible synthetic amorphous silica particles that can be produced with a large surface area and a range of pore sizes
Ingredients

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

The drug for treatment of multiple CNS conditions will be reformed into a novel patentable form to potentially improve delivery and give more intellectual property protection
Digital

Documentation complexity at crisis point?

Do we focus too much on the paperwork, to the detriment of product and patients? Has documentation become so complex it’s become a dangerous distraction and your biggest risk? by Martin Lush
Subscribe now